Ling Su,
PhD
Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures
Dr. Su is an epidemiologist and drug development professional with 25 years of industry and government experience in the US and Asia. His extensive experience spans the fields of regulatory affairs, medicinal product development strategy, clinical research, drug safety, and pharmacoepidemiology. Dr. Su is currently a Professor and Director of the Institute of Drug Regulatory Science at Shenyang Pharmaceutical University, China and a Venture Partner at Lilly Asia Ventures, based in Shanghai, China. Previously serving as the Strategic Advisor for Life Sciences at Sidley Austin and as Senior Vice President and Head of Development Greater China Region at Novartis, Dr. Su has held various research and development and management positions at Merck, Roche, and Wyeth/Pfizer. Prior to joining the private sector, he worked in the Bureau of Drugs, Ministry of Health in China and in the US FDA’s Center for Drug Evaluation and Research (CDER).
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Fellows of DIA
-
PhD •Chair, Fellows of DIA
President, Japan Self-Medication Industry -
-
JD • President, B-Henry & Associates -
MD, PhD • Pharmacovigilance Expert -
MD • Professor of Clinical Pharmacology, St. Vincent's Hospital -
MBA • President, International Regulatory Affairs Group LLC -
MPH, PhD • Global Chief, Sci Affairs; Sr VP, Head, Center for Advanced Evidence Generation
IQVIA -
PhD • Senior Advisor, Strategic Programs,Center for Drug Evaluation and Research, US Food and Drug Administration -
MD • Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ, Eisai Co., Ltd. -
MBA • Chairman, CISCRP; Director of Sponsored Research, Tufts Center For the Study of Drug Development -
PhD • Corporate Vice President
PAREXEL International -
MD • Senior Vice-President, Industrie Sante -
MD • Deputy Director, FDA Liaison to the EMA, Office of International Programs, OC -
MD • Deputy Director, Integrated Delivery, and Lead for Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation -
MD, JD • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety, Merck & Co., Inc. -
MS • Representative, NM Consulting -
PhD • Advisor, Digital Channels and eCapabilities, Eli Lilly and Company -
MD • Chief Medical Officer & EVP, Horizon Pharma, Inc. -
DVM, MBA • Director Biopeople, University of Copenhagen -
PhD • Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures